Introduction {#Sec1}
============

SARS-CoV-2 infection can be paucisymptomatic or lead to the coronavirus disease-2019 (COVID-19), which has a very large pattern of disease severity, in particular in patients with cardiovascular comorbidities \[[@CR1]\]. COVID-19 infection is associated with a coagulopathy characterized by an increase in procoagulant factors such as fibrinogen, together with a strong elevation of D-dimers that have been associated with a higher mortality \[[@CR1], [@CR2]\]. Increased incidence of pulmonary embolism has been observed in several reports \[[@CR3]\] and microvascular thrombosis in the lungs has been noted in autopsies series and in COVID-19 acute respiratory distress syndrome (ARDS) \[[@CR4]--[@CR6]\]. This microvascular thrombosis is observed while an inflammatory storm including IL-6 occurs in COVID-19 patients leading to the activation and recruitment of leukocytes. Activated leukocytes are able to damage capillary endothelium and to disrupt the thrombo-protective state of endothelial cells, probably participating to microvascular thrombosis. SARS-CoV-2 virus has been shown to infect blood vessels and induce vascular damage in vitro and in vivo \[[@CR7]--[@CR9]\]. SARS-CoV-2 can infect cells via the angiotensin-converting enzyme 2 (ACE2) receptor which is ubiquitous but largely expressed in endothelial cells \[[@CR10]\]. In this report, more than the presence of virus in endothelial cells, authors describe both inflammation and endothelial cell death. This endotheliitis could be at the origin of impaired microcirculatory function affecting particularly the lungs and kidneys \[[@CR8], [@CR11]\].

Thrombo-inflammation has been described in arterial and/or venous thrombosis but also in cancer associated thrombosis with the complex interplay between blood coagulation and inflammation \[[@CR12]\]. Markers of activation of endothelium such as soluble endoglin, soluble E-selectin (sE-selectin) or angiopoietin-2 have been involved in hemostasis, thrombo-inflammatory events or sepsis \[[@CR13]--[@CR15]\]. Indeed, endothelial activation has been found as a major determinant that mediates cerebral ischemia/reperfusion injury by promoting thrombo-inflammation \[[@CR16]\].

Therefore, the aim of our study was to identify, in COVID-19 patients with criteria of hospitalization, soluble circulating endothelial and/or angiogenic markers at admission that could predict the need for hospitalization in intensive care unit (ICU) -- *i.e.,* respiratory failure and requiring mechanical ventilation -- and anticipate subsequent disease worsening.

Patients and methods {#Sec2}
====================

Study design and population {#Sec3}
---------------------------

This study was an observational cohort study conducted in Georges Pompidou European hospital in Paris (France). Consecutive patients with suspected SARS-CoV-2 infection were prospectively included. Inclusion criteria were an age over 18 years old, an infectious syndrome, a suspected COVID-19 with hospitalization criteria either in conventional wards or directly to ICU. All COVID-19-suspected patients were tested for SARS-CoV-2 infection by nasopharyngeal swabs and screened for hospitalization criteria based on local guidelines. For each included patient, clinical evaluation, chest computed tomography (CT) scan, and biological evaluation were performed. Baseline characteristics (demography, usual treatments, clinical manifestations, cardiovascular risk factors, and body mass index), biological data were retrieved from the computer-based patient records using a standardized data collection. For confirmation cohort of E-selectin expression, we used data from 32 patients with confirmed SARS-CoV-2 infection and various disease severity from Cochin Hospital in which a whole blood gene expression profile analysis was made using the Nanostring nCounter immunology panel. Healthy controls were asymptomatic adults, matched with cases on age with a negative SARS-CoV-2 RT-PCR testing at time of inclusion.

Both studies conformed to the principles outlined in the Declaration of Helsinki, and received approval by the appropriate Institutional Review Board (CPP2020-04-048/2020-A01048-31 / 20.04.21.49318).

Routine blood examinations {#Sec4}
--------------------------

All samples were collected on EDTA, sodium heparin and 0.129 M trisodium citrate tubes (9NC BD Vacutainer, Plymouth, UK). Routine lab tests were complete blood count, creatinine, C-reactive protein (CRP) and high sensitivity cardiac troponin (Hs-cTnI, Beckman) on a DXI analyzer \[[@CR17], [@CR18]\]. Platelet poor plasma (PPP) was obtained after centrifugation twice at 2500 g for 15 min. Coagulation tests were PT ratio, fibrinogen and soluble fibrin monomer level (STA®-Liatest FM; Diagnostica Stago) explored on a STA-R® Max coagulometer (Stago) as previously described \[[@CR19]\]. D-dimer concentrations were determined using the Vidas D-Dimer assay (BioMérieux) according to the manufacturer's instructions. PPP was frozen after a second centrifugation at 2500 g for 15 min and stored at − 80 °C until analysis of vascular markers. Soluble E-selectin, endoglin, VEGF-A, PlGF, basic-FGF, VEGFR-2, angiopoietin-1 and -2, c-Kit and leptin concentrations were quantified in PPP with a Human Magnetic Luminex Assay from R&D systems (Lille, France). Data were assessed with the Bio-Plex 200 using the Bio-Plex Manager 5.0 software (Bio-Rad, Marnes-la-Coquette, France).

Gene expression analysis {#Sec5}
------------------------

As previously described \[[@CR20]\], we analyzed 100 ng (5 μl) of total RNA from each sample using the Nanostring Human Immunology kit v2 according to the manufacturer's instructions. The housekeeping genes were selected from the 15 candidate control genes provided by Nanostring, following the geNorm method. Briefly, after selection of genes with all values above the background level, for each two genes *j* ≠ *k*, pairwise variation coefficient *V*~*jk*~ is defined as$$\documentclass[12pt]{minimal}
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                \begin{document}$${\text{V}}_{\text{jk}}\text{ } = \text{ s}{\text{d}}_{\text{i}}\left({\log}_{2}\left(\frac{{\text{a}}_{\text{ij}}}{{\text{a}}_{\text{ik}}}\right)\right)\text{,}$$\end{document}$$where *a*~*ij*~ is the number of counts for the gene *j* in the sample *i*. The gene stability measure *M*~*j*~ for control gene *j* is the arithmetic mean of all pairwise variations *V*~*jk*~ for *k* ≠ *j*. *M*~*j*~ evaluates the degree of correlation of gene *j* to other control genes (the smaller *M*~*j*~ is, the more correlated gene *j* is to other control genes). Genes were ranked by increasing *M*, and to determine a threshold, the normalization factors NF~*n*~ was computed for all *n* (defined as the geometric mean of the housekeeping gene counts) of each sample when considering the *n* genes with lowest *M* as a housekeeping gene set. Correlations between consecutive normalization factors increased then decreased when adding the 6th gene with lowest *M*. This threshold was confirmed by studying the pairwise variation between consecutive NF~*n*~s. The final housekeeping gene set consisted of the following 5 genes: *TUBB, GUSB, SDHA, TBP, ABCF1*. Normalization was performed as follows: the scaling factor for a sample was defined as the ratio of the average across all geometric means and the geometric mean of the sample. For each sample, all gene counts were multiplied by the corresponding scaling factor.

Respiratory mechanics and gas exchange {#Sec6}
--------------------------------------

To evaluate the association between the level of angiopoietin-2 as a circulating endothelial and/or angiogenic markers and the pathophysiological process leading to severe respiratory failure (i.e., with the need of invasive mechanical ventilation), we analyzed respiratory measurements among 17 COVID-19 patients that fulfilling Berlin criteria for moderate or severe ARDS. Corresponding data were obtained while patients were ventilated using a high positive end-expiratory pressure (PEEP) strategy, as part of our respiratory bundle in such patients \[[@CR10]\]. We present measurements obtained early during the invasive mechanical ventilation (IMV*)* course in deeply sedated and paralyzed patients. Importantly, no patient suffered from pulmonary embolism at the time of measurements. All patients were ventilated using the CareScape R860 ventilator (GE Healthcare, USA) allowing the following measurements:Respiratory mechanics: plateau pressure (Pplateau), total PEEP (PEEPtot), driving pressure (DP), respiratory system compliance (Crs), end-expiratory lung volume (EELV) as determined by the nitrogen washing-washout method.Gas exchanges: PaO~2~/FiO~2~ ratio

Statistical analysis {#Sec7}
--------------------

Continuous data were expressed as median \[interquartile range: (IQR)\] and categorical data as proportion. Patients were compared according to level of care (hospitalization in conventional medical unit or hospitalization directly in ICU). In this univariate analysis, we determined the differences in median using the unpaired *t*-test (Mann--Whitney U test) for continuous variable and differences in proportions were assessed with the Chi-square test or Fischer exact test if necessary.

We generated receiver operating characteristics (ROC) curves with a regression logistic model that included the angiopoietin-2 to assess the predictability of hospitalization in ICU. We calculated the area under the curve (AUC) and to obtain the optimal cut-off points we used the Youden index method \[[@CR21]\]. We used logistic regression to assess the association between the level of angiopoeitin-2 (as a categorical variable dichotomized according to the cutoff of 5000 pg/mL) and the hospitalization in ICU. We performed 4 different logistic models that included Angiopoeitin-2: (i) unadjusted (the angiopoeitin-2 only); (ii) adjusted on the plasma creatinine level; (iii) adjusted on the D-dimers level; and (iv) adjusted on the CRP level. Plasma creatinine, D-dimers and CRP were included in the model as a categorical variable dichotomized according the median. We performed the correlation between routine biomarkers (plasma creatinine, D-dimers and CRP), vascular biomarkers (angiopoietin-2 and sE-selectin) and respiratory measurements (Pplateau, PEEPtot, DP, Crs, EELV). Each correlation was assessed using the Kendall coefficient correlation test.

For whole blood gene expression analysis of 32 patients and 13 healthy donors from Cochin hospital gene, data were imported into nSolver analysis software (version 2.5) for quality checking, then exported as a table, and all subsequent analyses were performed using R version 4.3, using ggplot2 for plots. Background level was computed as mean + 2 standard deviation of the negative control probes, for all samples. We then compared the level of E-selectin normalized RNA count between the 3 groups (control, patients hospitalized in medical conventional wards and patients hospitalized in ICU) using the Kruskal--Wallis test followed by Dunn's post-test for multiple group comparisons with median reported; \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.

All analyses were 2-sided and a *p*value of *p* \< 0.05 was considered statistically significant. Statistical analysis was performed using R studio software (R Development Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria).

Results {#Sec8}
=======

sE-selectin and angiopoietin-2 at entrance in hospital are discriminant biomarkers for direct ICU admission {#Sec9}
-----------------------------------------------------------------------------------------------------------

The study cohort included 40 consecutive patients who presented at the emergency department and were diagnosed positive for COVID-19. They were divided into two groups: patients hospitalized in medical conventional wards (*n* = 20) and patients directly admitted to the ICU (*n* = 20). The two populations were strictly comparable in terms of age and time from onset of first symptoms (Table [1](#Tab1){ref-type="table"}). However, COVID-19 patients directly admitted to the ICU had a significant lower SpO2 (*p* = 0.003) and higher respiratory rate-breath per minutes (*p* = 0.003). COVID-19 patients admitted in ICU had a more pronounced lymphopenia (*p* = 0.038, Table [2](#Tab2){ref-type="table"}). Regarding hemostasis, COVID-19 patients admitted in ICU had higher D-dimer levels at entrance (*p* = 0.008). No difference in PT ratio was observed between groups (Table [2](#Tab2){ref-type="table"}). Fibrin monomers being negative and fibrinogen level elevated, results were not in favor of a COVID-19 associated disseminated intravascular coagulation at admission. Also, COVID-19 patients admitted in ICU had significantly higher CRP level (*p* = 0.002) and serum creatinine levels (*p* = 0.001).Table 1Demographic and clinical characteristics of COVID-19 patients at admission according to level of care (medical ward or ICU)Medicine patients (*n* = 20)ICU patients*p*value(*n* = 20)Male sex---*n* (%)11 (55)17 (85)0.084Age---years\*, median \[IQR\]53 \[37, 65.4\]59.5 \[54.25, 70.5\]0.11BMI---kg/m^2^\*26.6 \[24.4, 27.6\]29.1 \[23.9, 31.6\]0.487Time from illness onset to hospital admission---days\*5.5 \[3, 7\]6.5 \[4, 8.3\]0.215CV risk factors, *n* (%) Hypertension6 (30)10 (50)0.333 Dyslipidemia3 (15)7 (35)0.273 Diabetes2 (10)6 (30)0.127 Sedentarity0 (0)2 (10)0.198 Chronic kidney disease1 (5)2 (10)0.99Medical history, *n* (%) Cancer1 (5)1 (5)0.99 Coronary heart disease0 (0)2 (10)NA Stroke2 (10)1 (5)0.99Treatments, *n* (%) Statins3 (15)3 (15)0.193 Oral antidiabetic agents1 (5)5 (25)0.184 Insulin1 (5)2 (10)0.99 β-blocker1 (5)2 (10)0.99 Calcium channel blockers1 (5)4 (20)0.339 ACEi or ARBs3 (15)8 (40)0.157 ARBs2 (10)5 (25)0.207 Diuretics1 (5)3 (15)0.598Clinical features, *n* (%) Fever20 (100)19 (95)0.99 Headache7 (35)12 (60)0.205 Cough18 (90)16 (80)0.658 Productive cough3 (15)2 (10)0.99 Dyspnea9 (45)18 (90)0.007 Myalgia7 (35)8 (40)0.99 Diarrhea4 (20)3 (15)0.99 Pneumonia16 (80)19 (95)0.339 SpO2---%^a^95 \[91.8, 97\]90 \[87, 92.3\]0.003 Respiratory rate---Breathes per min\*18 \[16, 20\]22 \[21, 38\]0.003 Pulse---Beats per min\*92 \[81.5, 112.5\]95 \[83.5, 106\]0.953*ICU* intensive care unit, *BMI* body mass index, *CV* cardiovascular, *ACEi* angiotensin conversion enzyme inhibitor, *ARB-2* antagonist of angiotensin 2 receptor blocker, *SpO2* pulse oximetric saturation, *ARDS* acute respiratory distress syndrome, *IQR* interquartile range, *CRP* C-reactive protein\*Variable expressed as median \[IQR\]Table 2Biological characteristics of COVID-19 patients at admission according to level of care (medical ward or ICU direct admission)Medicine patients (*n* = 20)ICU patients (*n* = 20)*p* valueBiological parameters, median \[IQR\] White blood cells---× 10^9^ per L6.15 \[4.30, 7.45\]7.20 \[4.75, 11.25\]0.267 Hemoglobin---g/L143 \[127.8, 152.5\]128 \[120.5, 139\]0.066 Platelet count---× 10^9^ per L205.5 \[151.3, 238\]165 \[135, 217\]0.361 Polynuclear neutrophils---× 10^9^ per L4.43 \[3.10, 5.53\]4.38 \[3.58, 10.48\]0.187 Lymphocytes---× 10^9^ per L0.95 \[0.80, 1.35\]0.68 \[0.46, 1.10\]0.038 Monocytes---× 10^9^ per L0.38 \[0.29, 0.55\]0.33 \[0.19, 0.62\]0.391 CRP---mg/L76.8 \[31.9, 101.2\]146 \[101.3, 204.8\]0.002 Plasma creatinine---µmol/L67 \[61.3, 83.5\]115 \[76.5, 215.5\]0.001 PT ratio0.96 \[0.94, 0.10\]0.88 \[0.81, 12\]0.132 Fibrinogen---g/L5.3 \[4.6, 5.9\]6.3 \[5.4, 6.7\]0.019 D-dimers ≥ 1000 ng/mL---*n* (%)6 (30)12 (60)0.069 D-dimers---ng/mL732 \[512, 1063\]1128 \[885, 2151\]0.008 Fibrin monomers---µg/mL \< 7 \[\< 7, \< 7\] \< 7 \[\< 7, \< 7\]0.270Angiogenic parameters (pg/mL), median \[IQR\] Angiopoietin-14139.4 \[3042.2, 8755.5\]5083.2 \[2928.5, 7349.9\]0.935 Soluble endoglin1958.6 \[1357.5, 2421.6\]1934.9 \[1568.8, 2255.1\]0.925 Leptin8531.4 \[5059.2, 19,938.5\]11,400.7 \[5724.1, 25,004.7\]0.552 Soluble E-selectin37,930.5 \[22227.1, 45,844.3\]52,937.6 \[35649, 71964\]0.009 VEGF-A23.6 \[17.5, 34\]24.5 \[16.9, 34.5\]0.839 Angiopoietin-24385.7 \[3185.9, 5667.1\]6574.1 \[5354.4, 11,375.9\]0.003 c-Kit12,809.7 \[10535.3, 22,153.7\]10,176.4 \[6353.1, 22,024.2\]0.218 FGFb48.9 \[34.2, 58.9\]45 \[34.8, 63.7\]0.935 PlGF42 \[36.4, 47.6\]43.7 \[35.2, 53.4\]0.482 sVEGFR-215,153.2 \[11619.2, 16,659.6\]13,097.5 \[10482.7, 17926\]0.646*ICU* intensive care unit\*Variable expressed as median \[IQR\]

We then analyzed plasma levels of vascular cytokines. In the ICU group, sE-selectin and angiopoietin-2 levels were significantly increased (*p* value at 0.009 and 0.003, respectively) (Table [1](#Tab1){ref-type="table"}), while other biomarkers were comparable between groups (Table [1](#Tab1){ref-type="table"}). Interestingly, sE-selectin and angiopoietin-2 levels were correlated (*r* = 0.25, *p* = 0.004) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Correlations between plasma angiopoietin-2 and sE-selectin levels in COVID-19 patients. R for Kendall rank correlation coefficient

To confirm at gene level the increase of circulating endothelial biomarkers, we analyzed an independent COVID-19 cohort of 32 patients with various disease severity (21 patients in Medicine and 11 patients in ICU), for which whole blood gene expression analysis was performed \[[@CR20]\]. Critically ill ICU COVID-19 patients had a significant increased expression of E-selectin with a grade-dependent manner (Fig. [2](#Fig2){ref-type="fig"}, *p* = 0.007).Fig. 2E-selectin gene expression profile according to admission of patients in medical ward or ICU versus controls. ICU for intensive care unit; RNA for Ribonucleic Acid; Difference between groups evaluated with Kruskal--Wallis test

Angiopoietin-2 level at admission is the most relevant factor to predict transfer to ICU {#Sec10}
----------------------------------------------------------------------------------------

In the thrombo-inflammation context of COVID-19, and since D-dimers, CRP and creatinine at admission were associated to transfer to ICU; we analyzed the association of sE-selectin and angiopoietin-2 with these three markers. While a significant association was found between sE-selectin and both CRP and creatinine (respectively with *p* value at 0.04 and 0.006), no association existed with D-dimers (*p* value at 0.22) (Fig. [3](#Fig3){ref-type="fig"}a, b, c). In contrast, angiopoietin-2 levels were significantly associated with CRP, creatinine and D-dimers (respectively with *p* value at 0.001, 0.001 and 0.003) (Fig. [3](#Fig3){ref-type="fig"}d, e, f).Fig. 3Correlations between E-selectin and angiopoietin-2 and biological parameters of thrombo-inflammation. **a**--**c** correlations between sE-selectin and CRP, plasma creatinine and D-dimers. **d**--**f**: correlations between angiopoietin-2 and CRP, plasma creatinine and D-dimers. R for Kendall rank correlation coefficient

ROC curve analysis was performed to define the optimal cut-off of angiopoietin-2 level to predict admission to ICU (Fig. [4](#Fig4){ref-type="fig"}). We identified angiopoietin-2 above 5000 pg/mL as potential inclusion criteria for ICU entrance in COVID-19 patients (AUC 77.2, 95% CI 62.4--91.9). Using this cut-off, ROC curve yielded a sensitivity of 80.1% (95% CI 55--93), a specificity of 70% (95% CI 45--87), a positive predictive value of 72.7% (95% CI 49--88) and a negative predictive value of 77.7% (95% CI 51%--92%) (Fig. [4](#Fig4){ref-type="fig"}). Table [3](#Tab3){ref-type="table"} confirms the link between angiopoietin-2 cut-off at 5000 pg/mL and ICU outcome using a logistic regression model (OR 9.33, 95% CI 2.35--44.91, *p* = 0.003). Strikingly, when adjusted to D-dimers, CRP or creatinine, the adjusted OR remained significant (*p* value at 0.009, 0.01, and 0.04, respectively).Fig. 4ROC curve for angiopoietin-2 cut-off in direct ICU admission. Angiopoietin-2 level above 5000 pg/mL was identified using Youden index method as a potential criteria for COVID-19 transfer in ICU (AUC 77.12, 95% CI 62.4--91.9). AUC for area under the curve; CI for confidence interval; PPV for positive predictive value; NPV for negative predictive value. R for Kendall rank correlation coefficient; CRP for C-reactive proteinTable 3Logistic regression model evaluating angiopoietin-2 cut-off at \> 5000 pg/mL for ICU outcome in COVID-19 patientsLogistic regression modelOR univariable (95% CI)OR multivariable (95% CI)1Angiopoietin-2 \> 5000 pg/mL9.33 (2.35--44.91, *p* = 0.003)--2Adjusted on creatinine5.18 (1.08--29.29, *p* = 0.04)3Adjusted on CRP6.96 (1.57--36.13, *p* = 0.01)4Adjusted on D-dimers7.34 (1.77--36.20, *p* = 0.009)We performed 4 separated logistic models: (1) unadjusted (Angiopoietin-2 level only); (2) adjusted on the plasma creatinine level; (3) adjusted on the D-dimer level; and (4) adjusted on the CRP levelPlasma creatinine, D-dimers and CRP were included in the model as a categorical variables dichotomized according the median: OR for Odds Ratio; CRP for C-reactive protein

High level of angiopoietin-2 at hospital entrance is correlated to decreased respiratory system compliance {#Sec11}
----------------------------------------------------------------------------------------------------------

To confirm the relevance of angiopoietin-2 levels with the clinical course and disease severity of COVID-19 patients, we explored the relationship between angiopoietin-2 levels at admission and respiratory mechanic and gas exchange values in 17 consecutive patients admitted to the ICU and requiring IMV. Strikingly, a significant negative correlation was observed between angiopoietin-2 level and Crs (mL/cmH~2~O, *r* = − 0.46, *p* = 0.01), while no significant correlations were found with other parameters (Table [4](#Tab4){ref-type="table"}).Table 4Correlation between angiopoietin-2 level and respiratory mechanic and gas exchange measurements in 17 COVID-19 ARDS patientsCorrelation coefficient with angiopoietin-2 level*p* valueRespiratory mechanics, median \[IQR\] Pplateau (cmH~2~O)27 \[25, 28\]0.260.16 PEEPtot (cmH~2~O)16 \[16, 18\]0.010.99 DP (cmH~2~O)10 \[9, 12\]0.270.15Crs (mL/cmH~**2**~**O)**39 \[33, 42.50\]− 0.460.01EELV (mL)2101 \[1790, 2447\]− 0.270.14Gas exchanges, median \[IQR\] PaO~2~/FiO~2~185 \[168, 284\]− 0.050.77 Angiopoietin-2 pg/mL (median \[IQR\])9743.54 \[5787.62, 12,289.77\]----The correlations between variables were assessed using the Kendall rank correlation test

Discussion {#Sec12}
==========

In this prospective study, we hypothesized that SARS-CoV-2 infection could induce endothelial dysfunction at the origin or associated to microvascular pulmonary damage. We provided evidence that levels of soluble endothelial markers of activation, i.e., sE-selectin and angiopoietin-2 were increased in critically ill COVID-19 patients. Angiopoietin-2 was the best biomarker to predict transfer to the ICU and was associated with poor lung compliance in COVID-19 patients.

Endothelial dysfunction and/or impaired angiogenesis may contribute to microvascular dysfunction in all organs. Markers of endothelial dysfunction and angiogenesis were shown to be predictors of disease severity in heart failure \[[@CR22]\], in renal failure \[[@CR23]\] and after cardiac surgery \[[@CR24]\]. Circulating biomarkers of endothelial activation and/or injury can be both the cause and/or the consequence of microvascular dysfunction. Integrity of endothelial cells allows providing an antithrombotic environment that is reversed upon the burst of inflammation related to IL-6 in COVID-19 patients. Therefore, this endothelial thrombo-protective barrier is disrupted, probably leading to the coagulopathy largely described in COVID-19 patients, along with a highly increased level of D-dimers related to in-hospital mortality \[[@CR1], [@CR2]\]. The thrombo-inflammation and impaired immune response associated with endothelial dysfunction can be reflected by circulating markers in pre-eclampsia or in cancer associated thrombosis. Indeed, for example in pre-eclampsia, the soluble endoglin or placental growth factor are now well recognized biomarkers of renal or endothelial damage, but also of oxidative stress secondary to the pathophysiological changes that precede the clinical onset of pre-eclampsia \[[@CR25]\].

In COVID-19, the hypothesis of kidney microthrombosis was proposed since the elevation of serum creatinine was associated with higher levels of D-dimers (\> 500 ng/mL) \[[@CR26]\]. The SARS-CoV-2 receptor (ACE2) is strongly expressed in endothelial cells \[[@CR10]\]. Infection of endothelial cells could therefore induce endothelial lesions triggering massive activation of coagulation and diffuse microthrombotic process impairing renal function and respiratory mechanics and gas exchanges. To explore this hypothesis, we quantified a panel of soluble markers exploring the endothelial dysfunction and angiogenesis and found increased levels of E-selectin and angiopoietin-2 in COVID-19 patients directly admitted to the ICU. These two markers are both increased in the context of inflammation and/or activation of endothelial cells. Indeed, E-selectin (CD62E) is a leukocyte adhesion molecule expressed on activated endothelial cells. Endothelial cells from normal skin and bone marrow \[[@CR27]\] or in infantile hemangioma \[[@CR28]\] constitutively express E-selectin, contrasting with endothelial cells from other tissues that do not constitutively express it. However, its expression is strongly upregulated by inflammatory cytokines \[[@CR29]\]. Soluble form of E-selectin is released during inflammation and has been widely proposed as a biomarker of endothelial dysfunction, in particular in sepsis \[[@CR30]\]. Interestingly, targeting E-selectin is currently evaluated for the treatment of venous thrombosis and associated inflammatory events \[[@CR14]\]. Thus, increased circulating sE-selectin together with increased mRNA confirm the endothelial dysfunction during COVID-19 disease and its relationship with severity. mRNA E-Selectin expression was indeed quantified within a huge panel of genes detected with Nanostring, mainly focusing on \"immunology genes\" \[[@CR20]\]. E-selectin and Angiopoietin-2 are both endothelial related molecules, respectively, present after endothelial activation on cell membrane for E-Selectin and in secreted molecule from the Weibel palade bodies for angiopoietin-2. However, as E-selectin was the only endothelial/angiogenic gene available in this panel, it was therefore used in the present work to confirm our protein data at the gene expression level. Importantly, results of mRNA E-selectin used in the present work allowed replicating the relevance of circulating endothelial proteins in an independent COVID-19 cohort and at the gene expression level. Recent published data on endotheliitis are in line with our results \[[@CR8]\]. Our results are, to our knowledge, the first proof of increased circulating markers of endothelial lesion in COVID-19 infection associated with severity.

Angiopoietin-2 is an angiogenesis regulator stored in Weibel Palade bodies, the endothelial storage organelles that contain multiple proteins, including von Willebrand factor. It can be rapidly released by activated endothelium upon thrombin or inflammatory cytokines. Angiopoietin-2 is part of the angiopoietin/tie-2 pathway, a crucial system regulating endothelial homeostasis, angiogenesis \[[@CR31]\] and proliferation \[[@CR32]\]. Angiopoietin-2 participates to the responsiveness of endothelium to inflammatory, hyperpermeability, apoptosis and vasoreactive stimuli but also induces inflammation and vascular hyperpermeability \[[@CR31]\]. Circulating angiopoietin-2 levels have been found increased in patients with sepsis or ARDS \[[@CR31]\] and predictive of mortality in ARDS patients \[[@CR33]\]. In the present work, angiopoietin-2 levels were significantly higher in patients admitted to the ICU by comparison to those admitted to conventional wards, confirming the importance of angiopoietin-2 pathway in endothelial inflammation. Angiopoietin-2 levels were associated to CRP and D-dimers, the latter reflecting the link between the Covid-19 coagulopathy and endothelial dysfunction. Since, angiopoietin-2 could reflect coagulopathy/inflammation and endothelial dysfunction; we explored its association with respiratory parameters in 17 IMV ICU COVID-19 patients. We found an association with Crs quantified early during the course of protective mechanical ventilation. As Crs could be a marker of the extent of the COVID-19 pulmonary insult, in link with alveolar damages, one can suspect than the pulmonary endothelial insult could be in parallel a co-marker of pulmonary disease severity. Thus, these results strongly support the role of diffuse microcirculatory dysfunction in critically ill COVID-19 patients, in addition to alveolar insult.

In conclusion, our data strongly support the relevance of levels of biomarker of endothelial dysfunction in COVID-19 patients at hospital admission, since vascular disorders and thrombosis seem to be a crucial point. Further prospective studies should evaluate the role of angiopoietin-2 to predict admittance in ICU but also to evaluate its prognostic value during the follow-up of patients and its relevance in respiratory and thrombotic related disorders. Such data could support the use of vascular protecting drugs or anticoagulation in the early phase of the disease to prevent respiratory and renal micro thrombotic manifestations during COVID-19 evolution.
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